

A Novel Role for Keratin 17 in Coordinating Oncogenic Transformation and Cellular Adhesion in Ewing Sarcoma

Savita Sankar,^a Jason M. Tanner,^a Russell Bell,^b Aashi Chaturvedi,^a R. Lor Randall,^{b,c} Mary C. Beckerle,^{a,d} Stephen L. Lessnick^{a,b,e}

Department of Oncological Sciences, Huntsman Cancer Institute, School of Medicine, University of Utah,^a Center for Children's Cancer Research, Huntsman Cancer Institute, University of Utah,^b Department of Orthopedics, Sarcoma Services, Huntsman Cancer Institute, University of Utah,^c Department of Biology, University of Utah,^d and Division of Pediatric Hematology/Oncology, School of Medicine, University of Utah,^e Salt Lake City, Utah, USA

Oncogenic transformation in Ewing sarcoma is caused by EWS/FLI, an aberrant transcription factor fusion oncogene. Glioma-associated oncogene homolog 1 (GLI1) is a critical target gene activated by EWS/FLI, but the mechanism by which GLI1 contributes to the transformed phenotype of Ewing sarcoma was unknown. In this work, we identify keratin 17 (KRT17) as a direct downstream target gene upregulated by GLI1. We demonstrate that KRT17 regulates cellular adhesion by activating AKT/PKB (protein kinase B) signaling. In addition, KRT17 is necessary for oncogenic transformation in Ewing sarcoma and accounts for much of the GLI1-mediated transformation function but via a mechanism independent of AKT signaling. Taken together, our data reveal previously unknown molecular functions for a cytoplasmic intermediate filament protein, KRT17, in coordinating EWS/FLI- and GLI1-mediated oncogenic transformation and cellular adhesion in Ewing sarcoma.

Ewing sarcoma is a highly aggressive bone- and soft tissue-associated malignancy that affects children and young adults (1). The vast majority of these tumors are characterized by a t(11;22)(q24;q12) chromosomal translocation, which generates a fusion oncogene, *EWS/FLI* (2). Persistent expression of *EWS/FLI* is necessary for maintenance of the transformed phenotype in Ewing sarcoma (3–5). Previous studies demonstrated that Ewing sarcoma tumors have a relatively low frequency of mutations in known oncogenes and tumor suppressors, supporting the concept that *EWS/FLI* is largely responsible for oncogenic transformation (6, 7). *EWS/FLI* functions as an aberrant transcription factor and dysregulates the expression of a myriad of target genes (8–10). Over the years, several critical *EWS/FLI* target genes have been identified, which are all necessary for maintenance of oncogenic transformation in Ewing sarcoma; however, no target gene alone has proven to be sufficient for *EWS/FLI*-mediated oncogenic transformation (3, 4). These findings highlight the unique biology of Ewing sarcoma and its sole reliance on a single oncogenic transcription factor, *EWS/FLI*, as the central regulator of a hierarchy of transcriptional networks.

Hedgehog signaling is of critical importance during development in regulating tissue patterning and stem cell maintenance (11, 12). This signaling pathway is inappropriately activated in a diversity of cancers (13–22). *GLI1* is a zinc finger transcription factor and is the principal effector of the Hedgehog signaling pathway (11). Previous microarray studies and a recent RNA sequencing (RNA-seq) experiment have identified *GLI1* as an *EWS/FLI*-upregulated target gene in Ewing sarcoma (3, 10, 23). *EWS/FLI* has been shown to bind and directly activate transcription from the *GLI1* promoter (24). Furthermore, loss-of-function approaches and pharmacological inhibition have demonstrated that *GLI1* is necessary for *EWS/FLI*-mediated oncogenic transformation (24–26). These studies highlight the importance of *GLI1* in Ewing sarcoma development.

However, the mechanism underlying *GLI1*-mediated oncogenesis in Ewing sarcoma and the critical transcriptional network of genes regulated by *GLI1* to achieve this function were unknown. Here we sought to define the mechanistic role of *GLI1* in

Ewing sarcoma, and in doing so, we identified a unique target gene, *KRT17*, that has novel functions in coordinating parallel functions of cellular adhesion and oncogenic transformation.

MATERIALS AND METHODS

Ethics statement. Patient tumor specimens were used in a deidentified way and were therefore deemed “nonhuman subject research” by the University of Utah Institutional Review Board via protocol IRB_00035414. Animal experiments were performed following approval from the University of Utah Institutional Animal Care and Use Committee.

Constructs and retroviruses. The luciferase-RNA interference (Luc-RNAi), *EWS/FLI*-RNAi (EF-2-RNAi), 3×FLAG-tagged *EWS/FLI* (3×FLAG *EWS/FLI*), and 3×FLAG *NKX2.2* cDNAs were described previously (3, 10, 27). The *GLI1* and *KRT17* short hairpin RNAs (shRNAs) were designed to target the cDNA and 3′ untranslated region (UTR), respectively, and were cloned into the pMKO.1 retroviral vector. The *GLI1* and *KRT17* shRNA sequences are provided in Table S1 in the supplemental material. N-terminally 3×FLAG-tagged constructs for *GLI1*, *KRT17*, and *KRT17* S44A cDNAs were generated and subcloned into the murine stem cell virus (MSCV) retroviral vector (Clontech). A 1-kb *KRT17* promoter including the 5′ UTR was cloned into the pGL3 basic vector (Promega), immediately upstream of the luciferase reporter gene. The constitutively active (myristoylated) *AKT* in the MSCV retroviral vector was described previously (28).

Cell culture. Ewing sarcoma cell lines (A673, TC-71, TC-32, SK-N-MC, and *EWS502*) and HEK293 EBNA cells were infected with retrovirus, and polyclonal populations were grown in the appropriate selection media, as previously described (4, 29). 3T5 growth assays were performed by

Received 1 March 2013 Returned for modification 11 April 2013

Accepted 29 August 2013

Published ahead of print 16 September 2013

Address correspondence to Stephen L. Lessnick, stephen.lessnick@hci.utah.edu.

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/MCB.00241-13>.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/MCB.00241-13

plating 1×10^5 cells per 10-cm tissue culture plates and counting and replating them at the same density every 3 days as previously described (29).

Soft agar and methylcellulose assays. Soft agar assays were performed as described previously (29). Methylcellulose assays were performed by plating 1×10^5 cells in 2% methylcellulose mixed with an equal volume of appropriate growth medium, as described previously (30).

Quantitative reverse transcriptase PCR. Total RNA was extracted by using an RNeasy kit (Qiagen). Total RNA from cells was then amplified and detected by using SYBR green fluorescence for quantitative analysis. Normalized fold enrichment was calculated by determining the fold change under each condition relative to the value for the control (either Luc-RNAi or Luc-RNAi reexpressing an empty vector). The data under each condition were then normalized to values for the internal housekeeping control genes *GAPDH* (the gene for glyceraldehyde-3-phosphate dehydrogenase) and *RPL19*. Primer sequences used to amplify target genes by quantitative reverse transcriptase PCR (qRT-PCR) are provided in Table S1 in the supplemental material.

Luciferase reporter assays. A 1-kb promoter region including the 5' UTR of *KRT17* was cloned into the pGL3 basic vector (Promega) immediately upstream of the luciferase reporter gene. Luciferase reporter assays were performed with HEK293 EBNA cells as previously described (31).

Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) was performed as previously described (32), by using anti-FLAG M2 magnetic beads (catalog number M8823; Sigma). Briefly, A673 cells expressing a GLI1-RNAi construct and reexpressing either an empty vector or a 3 \times FLAG GLI1 cDNA were used for the ChIP experiment. Quantitative PCR was performed with *KRT17* gene primers that amplify a region \sim 150 bp upstream of the transcription start site (TSS) that includes three putative GLI1 binding sites. Primers that amplify regions 5 kb upstream and 5 kb downstream of the TSS were used as negative controls. *ALB* (31) and gene desert (33) primers were used as normalization controls. Primer sequences used to amplify the *KRT17* promoter regions are provided in the Table S1 in the supplemental material.

Xenograft and intratibial injection assays. A673 or SK-N-MC Ewing sarcoma cells were infected, selected with a control ERG-RNAi or KRT17-RNAi, and injected into the flanks of nude mice at 1×10^6 cells per flank or 2.5×10^5 cells into the tibias of NOD/SCID mice. For the xenograft tumor assay, five mice each were injected subcutaneously with control knockdown cells or KRT17 knockdown cells. Both flanks of each mouse was injected subcutaneously. Under the control conditions, one mouse died due to the anesthesia and was censored from the analysis. Therefore, 8 control knockdown and 10 KRT17 knockdown tumors were measured. For the intratibial tumor assay, five mice were each injected into the right tibia with infected and selected A673 cells; therefore, 5 tumors were measured per group. Twelve mice were injected in the right tibia with infected and selected SK-N-MC cells; therefore, 12 tumors were measured per group. Tumors were measured by using digital calipers, and three-dimensional (3D) tumor volumes were calculated by using the equation (length \times width \times depth)/2. The mice in each group were sacrificed once their tumors reached size limits of 2 cm for the subcutaneous injection model and 1.5 cm for the intratibial injection model. The data from both assays were plotted as Kaplan-Meier survival curves by using GraphPad Prism.

Antibodies and reagents. The following antibodies were used for immunodetection: M2 anti-FLAG (horseradish peroxidase [HRP]) (catalog number A8592; Sigma), anti-FLI-1 (catalog number sc-356 \times ; Santa-Cruz), anti- α -tubulin (catalog number CP06; Calbiochem), anti-KRT17 (catalog number ab-53707; Abcam), anti-phospho-AKT (S473) (catalog number 9271S; Cell Signaling), anti-AKT (pan) (catalog number 4691S; Cell Signaling), and anti-GLI1 (catalog number 2643S; Cell Signaling). The isozyme-selective AKT inhibitor (Akti1/2) was obtained from Millipore (catalog number 124017). The inhibitor was used at a final concentration of 2 μ M. At this concentration, it inhibits all three forms of AKT

(AKT1, AKT2, and AKT3). Cells were treated with the inhibitor for 24 h before they were used for experiments.

Adhesion assay. Ewing sarcoma cells, infected and selected with different constructs, were seeded at 5×10^5 cells per well in a non-extracellular matrix-coated 24-well plate. Cells were allowed to adhere for 2 h at 37°C and were then processed as previously described (34). Cells that adhered were stained with toluidine blue, and the optical density (OD) was measured at 620 nm, as previously described (34).

Immunofluorescence assays. Sterile coverslips were coated with 10 μ g/ml fibronectin in 12-well plates overnight at 4°C. A total of 75×10^3 cells/well were seeded, allowed to adhere for 24 h, and fixed with 3.7% formaldehyde as described previously (34). Cells were stained with anti-paxillin antibody (1:100) for 1 h at 37°C and then with Alexa Fluor-secondary antibody (1:200) and Alexa Fluor-phalloidin and were imaged by using a Zeiss Axioskop2 Mot Plus microscope with a 40 \times objective, as previously described (34).

RNA sequencing analysis, GSEA, and Venn overlaps. RNA from A673 cells stably infected and selected for expression of a control Luc-RNAi or the KRT17-RNAi was extracted by using the RNeasy kit (Qiagen) with an on-column DNase digestion protocol. Libraries for deep sequencing were prepared according to the manufacturer's instructions (Illumina) and sequenced on an Illumina Hi-Seq instrument with 50 cycles of single-end reads. Sequences were aligned to human genome build hg19. The USeq analysis package was used to identify differentially expressed genes (<http://useq.sourceforge.net/>). Significance parameters were set to a 2-fold or 4-fold change in expression and a false discovery rate (FDR) of 0.1 (10%) or 1.0×10^{-10} .

Overlaps between the different gene sets were generated by using the VennMaster program (<http://www.informatik.uni-ulm.de/ni/mitarbeiter/HKestler/vennm/doc.html>). Statistical significance of the overlaps was determined by using chi-square analysis. Gene set enrichment analysis (GSEA) was performed by using the GSEA v2.0.10 program (<http://www.broad.mit.edu/gsea/>). Functional annotation analysis was performed by Database for Annotation, Visualization, and Integrated Discovery (DAVID) analysis (<http://david.abcc.ncifcrf.gov/>). Identification of potential direct GLI1 target genes was performed by using Find Individual Motif Occurrences (FIMO) (<http://meme.nbcr.net/meme/doc/fimo.html>).

RNA sequencing accession number. Raw data from the GLI1 RNA sequencing experiment can be found under NCBI Short Reads Archive number 121863.

RESULTS

GLI1 is a downstream target of EWS/FLI and is necessary for oncogenic transformation. Previous studies using loss-of-function approaches identified GLI1 as an upregulated target of EWS/FLI (25, 26). To further demonstrate that GLI1 is specifically regulated by EWS/FLI, we used a retroviral-based stable knockdown/rescue approach in A673 cells (a patient-derived Ewing sarcoma cell line). We found that reduction of EWS/FLI levels resulted in a significant reduction in the GLI1 expression level, which was restored by reexpression of an RNAi-resistant EWS/FLI cDNA (Fig. 1A; see also Fig. S1A in the supplemental material). This result demonstrated that GLI1 is specifically upregulated by EWS/FLI and is not an off-target or other nonspecific RNAi effect. EWS/FLI did not regulate GLI2 or GLI3 (see Fig. S1B). GLI1 is not the sole downstream effector of EWS/FLI-mediated oncogenic transformation because GLI1 expression (Fig. 1B) failed to rescue oncogenic transformation following knockdown of EWS/FLI (Fig. 1C; see also Fig. S1C in the supplemental material).

To test the necessity of GLI1 for Ewing sarcoma oncogenesis, we performed GLI1 knockdown/rescue experiments (Fig. 1D; see also Fig. S1D in the supplemental material). In comparison to a control knockdown (Luc-RNAi), GLI1 knockdown did not affect




FIG 1 GLI1 is upregulated by EWS/FLI and is necessary for oncogenic transformation in Ewing sarcoma cells. (A) Western blot analysis to demonstrate EWS/FLI-mediated activation of GLI1. GLI1 and EWS/FLI levels were assessed in A673 cells infected with a control shRNA (Luc) or an shRNA targeting EWS/FLI, followed by rescue with an empty vector or an RNAi-resistant EWS/FLI cDNA using anti-GLI1 and anti-FLI antibodies. Tubulin was used as a loading control. The asterisk indicates the 3×FLAG-tagged EWS/FLI cDNA that runs slightly higher than endogenous EWS/FLI. (B) Western blot analysis to demonstrate expression of the RNAi-resistant 3×FLAG-tagged EWS/FLI cDNA or 3×FLAG-tagged GLI1 cDNA constructs using an anti-FLAG antibody in A673 cells expressing a control shRNA (Luc) or an EWS/FLI shRNA. Tubulin was used as the loading control. (C) Quantification of colonies formed by A673 cells described above for panel B. Error bars indicate standard deviations of duplicate assays. *P* values were determined by using Student's *t* test, comparing all conditions to the control knockdown/empty vector condition (***, $P \leq 0.001$). (D) Western blot analysis of GLI1 levels in A673 cells infected with a control shRNA (Luc) or an shRNA targeting GLI1, followed by rescue with an empty vector or an RNAi-resistant GLI1 cDNA. Tubulin was used as a loading control. The asterisk indicates the 3×FLAG-tagged GLI1 cDNA that runs slightly higher than endogenous GLI1. (E) Growth assays (3T5) for the A673 cells described above for panel D. Student's *t* test showed no significant difference in growth curves. (F) Quantification of colonies formed in soft agar by A673 cells expressing a control shRNA (Luc) or a GLI1 shRNA, reexpressing an empty vector or RNAi-resistant GLI1 or NKX2.2 cDNA constructs. Error bars indicate standard deviations of duplicate assays. *P* values were determined by using Student's *t* test, comparing all conditions to the control knockdown/empty vector condition (**, $P \leq 0.01$).

monolayer growth of cells in tissue culture but significantly reduced colony growth in soft agar (Fig. 1E and F). This is not an “off-target” effect because reexpression of GLI1 rescued the loss of transformation induced by GLI1 knockdown (Fig. 1D to F). Importantly, knockdown or reexpression of GLI1 did not affect EWS/FLI expression (see Fig. S1E and F). These results demonstrated that GLI1 is necessary for maintenance of oncogenic transformation in Ewing sarcoma cells.

GLI1 has been shown to transcriptionally activate NKX2.2 (26). NKX2.2 is a critical target of EWS/FLI that is necessary for oncogenic transformation in Ewing sarcoma (3). We therefore asked if NKX2.2 could rescue GLI1 knockdown-mediated loss of transformation. Interestingly, we found that NKX2.2 (see Fig. S1G in the supplemental material) was unable to rescue the loss of transformation mediated by GLI1 knockdown (Fig. 1F), indicating that other GLI1 target genes are necessary for full oncogenic transformation in Ewing sarcoma.

Determining the transcriptional signature of GLI1 in Ewing sarcoma. We next sought to identify the full complement of genes regulated by GLI1 in Ewing sarcoma. We performed an RNA-seq experiment in A673 cells, comparing genome-wide transcripts from cells expressing control and GLI1-RNAi constructs (Fig. 2A; see also Table S2 in the supplemental material). VennMaster analysis was used to generate overlaps of the upregulated and down-

regulated gene sets obtained from the GLI1 RNA-seq and the EWS/FLI RNA-seq experiments (23). Of the 1,796 genes upregulated by EWS/FLI, 327 genes were also upregulated by GLI1 ($P = 3.19 \times 10^{-162}$) (Fig. 2B), and of the 2,227 genes repressed by EWS/FLI, 319 genes were also repressed by GLI1 ($P = 1.01 \times 10^{-170}$) (Fig. 2B), demonstrating that GLI1 contributes significantly to the EWS/FLI transcriptional profile in Ewing sarcoma cells. Using very stringent cutoffs of a 4-fold change and an FDR of 1.0×10^{-10} , we limited the list to 86 genes upregulated and 55 genes downregulated by GLI1 (see Table S2). We used this stringent set of genes to perform gene set enrichment analysis (GSEA) against EWS/FLI-regulated genes to better determine the relationship between the EWS/FLI and GLI1 transcriptional profiles. We found that the GLI1-upregulated genes clustered strongly with the most highly upregulated EWS/FLI genes (normalized enrichment score [NES] = 2.0; $P < 0.001$) and vice versa (NES = -1.8; $P < 0.001$) (Fig. 2C; see also Fig. S2A in the supplemental material), indicating that GLI1-regulated genes make up a significant portion of the EWS/FLI transcriptional signature. We next performed GSEA and VennMaster analysis of the RNA-seq-based GLI1-regulated genes identified in A673 cells against previously identified microarray-based EWS/FLI-regulated genes in TC71 and EWS502 Ewing sarcoma cells (4) and again found significant correlations and overlaps between GLI1 and EWS/FLI in gene regulation (see

target genes may contribute to the neuronal phenotype of Ewing sarcoma. Among the downregulated gene set, the most significant classes were related to signaling and membrane activity (Fig. 2D).

Identification of KRT17 as a direct downstream target of GLI1. To further investigate the role of GLI1 target genes identified from the RNA-seq analysis, we focused on *KRT17*, which is the second most upregulated GLI1 target gene (Fig. 2A) and is also regulated by EWS/FLI (Fig. 2B and C; see also Fig. S2A to E in the supplemental material). qRT-PCR analysis demonstrated that both GLI1 and EWS/FLI upregulate *KRT17* in multiple Ewing sarcoma cell lines (Fig. 3A to C). These results demonstrate that *KRT17* is an upregulated target of GLI1 in Ewing sarcoma.

The GLI1 RNA-seq analysis does not distinguish direct from indirect targets. GLI1 is a well-studied transcription factor, and previous work identified and characterized a conserved 10-bp motif as the preferred binding site (GACCACCCAC/A) for GLI1 on-target gene promoters (39, 40). To predict potential direct targets of GLI1, we used Find Individual Motif Occurrences (FIMO) (41), by combining a previously reported weighted matrix for binding affinity and a weighted matrix for the activation potential of GLI1 at the 10-bp motif, to search for genes in our RNA-seq data set that had a significant match (P value cutoff of 1.0×10^{-5}) to the known GLI1 binding motif. We identified 23 potential direct upregulated and 12 direct downregulated targets of GLI1 (see Fig. S3 in the supplemental material). Interestingly, *KRT17* was one of the potential direct targets of GLI1 (see Fig. S3). Directed chromatin immunoprecipitation assays demonstrated significant GLI1 binding to the *KRT17* promoter-proximal region (Fig. 3D). Luciferase reporter assays demonstrated a dose-dependent increase in luciferase activity from a 1-kb *KRT17* promoter region with increasing concentrations of GLI1 cDNA (Fig. 3E). These data indicate that *KRT17* is likely a direct upregulated target of GLI1.

KRT17 is expressed in Ewing sarcoma cell lines and primary tumor samples. Western blot analysis revealed that the *KRT17* protein is expressed at detectable levels in all Ewing sarcoma cell lines tested albeit at various levels (Fig. 4A). qRT-PCR analysis revealed a significant positive correlation between GLI1 and *KRT17* expression in a panel of Ewing sarcoma cell lines ($R^2 = 0.9$) (see Fig. S4A in the supplemental material). To validate this finding in primary Ewing sarcoma tumor samples, we performed maximum threshold cycle RT-PCR with five independent Ewing sarcoma primary tumors, which revealed that *KRT17* RNA is expressed in all tumor samples tested (Fig. 4B). We next performed qRT-PCR analysis to correlate expression levels of EWS/FLI and GLI1, and GLI1 and *KRT17*, in this limited set of primary tumor samples ($n = 5$). Interestingly, we identified a significant correlation between EWS/FLI and GLI1 expression ($R^2 = 0.984$) (Fig. 4C) and between GLI1 and *KRT17* expression ($R^2 = 0.975$) (Fig. 4C), highlighting the significance of the hierarchy of transcriptional regulation between EWS/FLI and GLI1 and between GLI1 and *KRT17*. To extend our findings further, we next analyzed the expression levels of GLI1 and *KRT17* in a publically available microarray data set (42) containing 20 EWS/FLI-positive Ewing sarcoma tumor samples. Again, we identified a moderate correlation ($R^2 = 0.577$) between GLI1 and *KRT17* expression in a larger number of Ewing sarcoma tumors (Fig. 4D). These data indicate that GLI1 positively regulates *KRT17* expression in Ewing sarcoma cell lines and primary tumors.

KRT17 is necessary for oncogenic transformation *in vitro* and *in vivo*. *KRT17* is a cytoplasmic intermediate filament protein

(43) that is overexpressed in several cancers (44–50). High *KRT17* expression levels correlate with poor prognosis in breast, pancreatic, and gastric adenocarcinomas (51–53). Basal cell carcinomas, which are associated with aberrant hedgehog signaling and, in turn, high GLI levels, express high levels of *KRT17*, which promotes tumor growth by modulating the immune response (44). However, it is unknown whether *KRT17* plays a more direct role in oncogenic transformation.

To determine if *KRT17* is involved in oncogenic transformation in Ewing sarcoma, we performed knockdown/rescue of *KRT17* in A673, EWS502, and SK-N-MC Ewing sarcoma cells. We found that knockdown of *KRT17* had no effect on cell growth in tissue culture but significantly reduced colony formation in soft agar (Fig. 5A to C; see also Fig. S5A to C in the supplemental material). Furthermore, reexpression of *KRT17* in knockdown cells (see Fig. S5E) restored their ability to form colonies in soft agar, demonstrating a specific function of *KRT17* in maintaining the transformed phenotype of Ewing sarcoma cells (Fig. 5C). Importantly, qRT-PCR analysis of endogenous *KRT17* transcript levels demonstrated that the *KRT17* knockdown was maintained even in the *KRT17* cDNA rescue samples (see Fig. S5F), suggesting that the rescue of oncogenic transformation was not merely due to a loss of *KRT17*-RNAi. *KRT17* knockdown had no effect on oncogenic transformation in a non-Ewing sarcoma cell line, HEK293 EBNA (human embryonic kidney cells) (see Fig. S5D), suggesting that *KRT17* is specifically required for oncogenic transformation in Ewing sarcoma.

We next used two *in vivo* tumor models, a subcutaneous model and an orthotopic intratibial model, to evaluate the role of *KRT17* in tumor growth *in vivo*. We noted a significant improvement in overall survival of immunocompromised mice injected with *KRT17* knockdown A673 cells compared to those with control (ERG) knockdown cells in both *in vivo* models (Fig. 5D and E). We extended these findings using SK-N-MC Ewing sarcoma cells in the orthotopic intratibial model and again noted a significant improvement in overall survival in the *KRT17* knockdown group compared to the control (ERG) knockdown group (Fig. 5F). In the tumors that did form in mice injected with *KRT17* knockdown cells, we noted that the knockdown effect was lost in tumors that grew actively, while the slow-growing (indolent) tumors from the opposite flanks of a few mice still maintained the *KRT17* knockdown (Fig. 5G; see also Fig. S5G in the supplemental material), indicating that *KRT17* is necessary for more aggressive tumor growth *in vivo*.

To evaluate if *KRT17* was a critical target gene downstream of GLI1, we performed anchorage-independent colony-forming assays with A673 cells following control or GLI1 knockdown and reexpression of an empty vector or the GLI1 or *KRT17* cDNA construct (see Fig. S5H in the supplemental material). Surprisingly, expression of the *KRT17* cDNA rescued the GLI1 knockdown-mediated loss of transformation (Fig. 5H). In cells harboring GLI1-RNAi and reexpressing the *KRT17* cDNA, maintenance of GLI1 knockdown and a lack of rescue of GLI1 target genes were demonstrated by qRT-PCR analysis (see Fig. S5I and J), indicating that the rescue of oncogenic transformation was not due to reexpression of GLI1 when *KRT17* was expressed. Importantly, knockdown or reexpression of *KRT17* did not have any effect on EWS/FLI or GLI1 expression (see Fig. S5K to N in the supplemental material). Taken together, these results demonstrate that *KRT17* is necessary for maintaining the transformed phenotype of




FIG 3 KRT17 is regulated by GLI1 in multiple Ewing sarcoma cell lines. (A) Validation of KRT17 as an EWS/FLI and GLI1 target gene. Shown are data for qRT-PCR analysis of KRT17 in A673 cells infected with a control shRNA (Luc), an EWS/FLI shRNA, or a GLI1 shRNA, followed by rescue with an empty vector, an RNAi-resistant EWS/FLI cDNA, or a GLI1 cDNA construct. Error bars indicate standard deviations. *P* values were determined by using Student's *t* test, comparing all conditions to the control knockdown/empty vector condition (**, $P \leq 0.01$; ***, $P \leq 0.001$). (B) Western blot analysis of cells described above for panel A, using KRT17, EWS/FLI, and GLI1 antibodies. Tubulin was used as the loading control. The red asterisks indicate the 3xFLAG-tagged EWS/FLI and GLI1 cDNAs. (C) qRT-PCR validation of KRT17 as a GLI1 target gene in multiple patient-derived Ewing sarcoma cell lines (TC71, TC32, SK-N-MC, and EWS502). Cells were infected with a control shRNA (Luc) or a GLI1 shRNA. GLI1 and KRT17 mRNA levels were analyzed. Error bars indicate standard deviations. *P* values were determined by using Student's *t* test, comparing all conditions to the control knockdown (Luc-shRNA) (**, $P \leq 0.01$; ***, $P \leq 0.001$). (D) ChIP of 3xFLAG GLI1 at the *KRT17* promoter in A673 cells expressing a GLI1-RNAi and reexpressing an empty vector or 3xFLAG GLI1 cDNA. An anti-FLAG antibody was used to chromatin immunoprecipitate 3xFLAG GLI1. The transcriptional start site (TSS) and a region ~150 bp upstream of the TSS with significant GLI1 binding are indicated. The level of enrichment for 3xFLAG GLI1 at the *KRT17* promoter in cells reexpressing the 3xFLAG GLI1 cDNA is plotted as normalized fold enrichment compared to the enrichment in the empty-vector-reexpressing cells, with the fold enrichment for each sample being compared to the average enrichment at two negative-control genes, *ALB* and a gene desert region in the genome. Enrichment of 3xFLAG GLI1 at regions 5 kb upstream and 5 kb downstream of the FIMO-identified binding sites were used as negative controls to further demonstrate binding specificity for GLI1 at the *KRT17* promoter. The error bars indicate standard deviations of a representative experiment. (E) Luciferase reporter assay with HEK293 EBNA cells cotransfected with a 1-kb *KRT17* promoter region upstream of luciferase or a control vector (that does not contain the *KRT17* promoter) and an empty vector or increasing concentrations of the GLI1 cDNA. Relative luciferase activity is the ratio of firefly luciferase activity to *Renilla* luciferase activity (to control for transfection efficiency). The red asterisks indicate potential GLI1 binding sites in the *KRT17* promoter. The error bars indicate standard deviations. *P* values were determined by using Student's *t* test, comparing all GLI1 cDNA-transfected conditions to the vector-transfected conditions (**, $P \leq 0.01$).




FIG 4 KRT17 is expressed in Ewing sarcoma cell lines and primary tumors. (A) Western blot analysis of KRT17 expression in multiple patient-derived Ewing sarcoma cell lines (A673, TC71, TC32, SKNMC, SKES1, and EWS502). Tubulin was used as the loading control. (B) Maximum threshold cycle RT-PCR analysis of KRT17 transcript levels in five independent Ewing sarcoma patient tumor samples compared to KRT17 transcript levels in A673 cells infected with a control shRNA (Luc) or a KRT17 shRNA as well as a water negative control. (C) Linear regression analysis to determine the correlation between EWS/FLI and GLI1 expression and between GLI1 and KRT17 expression in the patient tumor samples described above for panel B. The expression levels were determined by qRT-PCR and plotted as a percentage of the expression level of the housekeeping gene (*GAPDH*). The R^2 value is indicated. (D) Linear regression analysis to determine the correlation between GLI1 and KRT17 expression in a publically available microarray data set (Ohali sarcoma data set) consisting of 20 Ewing sarcoma tumor samples (42). The mRNA expression values for GLI1 and KRT17 in each tumor sample were obtained through Oncomine (<https://www.oncomine.org/>) and plotted as a percentage of the value for the housekeeping gene (*GAPDH*). The R^2 value is indicated.

Ewing sarcoma cells both *in vitro* and *in vivo* and that *KRT17* is a critical target gene downstream of *GLI1* that contributes significantly to *GLI1*-mediated maintenance of oncogenic transformation in Ewing sarcoma.

KRT17-mediated activation of AKT signaling is necessary and sufficient to regulate cellular adhesion in Ewing sarcoma. *KRT17* is known to regulate protein synthesis and epithelial cell growth by inducing phosphorylation and activation of the AKT protein (54). We therefore asked whether *KRT17* regulated AKT phosphorylation downstream of *GLI1* and if this genetic interaction was necessary for *KRT17* function in Ewing sarcoma. *GLI1* knockdown significantly reduced AKT phosphorylation levels in A673 cells, and this effect was rescued by *GLI1* or *KRT17* reexpression (Fig. 6A) but not by expression of the *KRT17* S44A mutant (Fig. 6B), a previously described mutant that fails to induce phosphorylation of AKT (54, 55), demonstrating that *KRT17* is the critical mediator of AKT phosphorylation downstream of *GLI1*.

To characterize the functional significance of *KRT17*-mediated activation of AKT signaling, we performed immunofluorescence studies on A673 cells expressing reduced levels of *KRT17*. The paxillin protein is a well-characterized marker of focal adhesions in cells (34). We therefore used paxillin staining as a measure of the adhesive capability of Ewing sarcoma cells. Interestingly, we noted a significant decrease in staining for paxillin protein in cells expressing reduced *KRT17* levels in comparison to control cells (Fig. 6C). As a control, EWS/FLI knockdown cells expressed higher levels of paxillin (Fig. 6C), as noted previously (34). To test if *KRT17* is directly involved in regulating cellular adhesion in Ewing sarcoma cells, we performed cellular adhesion assays with *KRT17* knockdown cells reexpressing wild-type *KRT17* or the S44A mutant. Interestingly, wild-type *KRT17*, but not the S44A mutant, rescued basal levels of cellular adhesion in Ewing sarcoma cells (Fig. 6D).

To directly test the contribution of active AKT signaling to




FIG 5 KRT17 is necessary for GLI1-mediated oncogenesis in Ewing sarcoma. (A) Western blot analysis of KRT17 in A673 cells infected with a control shRNA (Luc) or two different shRNA constructs targeting KRT17. Tubulin was used as the loading control. (B) Growth assays (3T5) for the A673 cells described above for panel A. Student's *t* test showed no significant difference in growth curves. (C) Quantification of colonies formed in methylcellulose by A673 cells expressing a control shRNA (Luc) or two different KRT17 shRNAs, reexpressing an empty vector or an RNAi-resistant KRT17 cDNA construct. Error bars indicate standard deviations of duplicate assays. *P* values were determined by using Student's *t* test, comparing all conditions to the control knockdown/empty vector condition (**, $P \leq 0.01$). (D to F) Survival curves for immunodeficient mice subjected to subcutaneous or intratibial injections with A673 cells or SK-N-MC cells expressing a control shRNA (ERG) or a KRT17 shRNA. Five mice and 12 mice were used per condition for the A673 cells and the SK-N-MC cells, respectively. For the subcutaneous model, both flanks of each mouse were injected subcutaneously. Under the control conditions, one mouse died due to the anesthesia and was censored from the analysis. Therefore, 8 and 10 tumors were measured for the control knockdown and KRT17 knockdown groups, respectively. For the intratibial model, the right tibia of each mouse was injected, and therefore, 5 tumors for the A673 group and 12 tumors for the SK-N-MC group were measured for both the control (ERG) knockdown and the KRT17 knockdown groups. The mice in each group in the subcutaneous model were sacrificed once their tumors reached a size limit of 2 cm^3 . The mice in each group in the intratibial model for both A673 and SK-N-MC cells were sacrificed once their tumors reached a size limit of 1.5 cm^3 . Percent survival was plotted for both models as Kaplan-Meier survival curves by using GraphPad Prism. The *P* values determined by log-rank test (Mantel-Cox test) using GraphPad Prism are indicated. (G) Western blot analysis of control (ERG) shRNA- or KRT17 shRNA-expressing tumors from the subcutaneous injection model described above for panel D. KRT17 levels in the tumors were compared to levels in the parental A673 cells expressing either the control shRNA or KRT17 shRNA, used to inject mice. Tubulin was used as the loading control. (H) Quantification of colonies formed in methylcellulose by A673 cells expressing a control shRNA (Luc) or a GLI1 shRNA and reexpressing the empty vector, 3×FLAG-tagged GLI1, or 3×FLAG-tagged KRT17 cDNA constructs. Error bars indicate standard deviations of duplicate assays. The *P* value was determined by using Student's *t* test, comparing the GLI1 knockdown/empty vector conditions to the control knockdown/empty vector conditions (***, $P \leq 0.001$).




FIG 6 KRT17 is necessary and sufficient for AKT phosphorylation-mediated cellular adhesion in Ewing sarcoma cells. (A) Western blot analysis of A673 cells infected with a control shRNA (Luc) or the GLI1 shRNA and reexpressing the empty vector, GLI1, or KRT17 cDNA constructs. The protein lysates from these cells were probed with phosphorylated AKT (S473), total AKT, and FLAG antibodies. Tubulin was used as a loading control. (B) Western blot analysis of A673 cells infected with a control shRNA (Luc) or a KRT17 shRNA and reexpressing an empty vector, the KRT17 wild-type, or an S44A mutant KRT17 cDNA construct. The protein lysates from these cells were probed with phosphorylated AKT (S473), total AKT, and KRT17 antibodies. The asterisks indicate 3 \times FLAG-tagged KRT17 and 3 \times FLAG-tagged S44A KRT17 cDNA constructs, which run slightly higher than endogenous KRT17. Tubulin was used as a loading control. (C) Immunofluorescence images of A673 cells infected with control shRNA (Luc), KRT17 shRNA, or EWS/FLI shRNA stained for focal adhesions (paxillin antibody) and for actin filaments (phalloidin). Arrowheads indicate paxillin-rich focal adhesions. (D) Adhesion assay with A673 cells infected with a control shRNA (Luc) or a KRT17 shRNA and reexpressing the empty vector, KRT17 wild-type, or S44A mutant KRT17 cDNA constructs. Error bars indicate standard deviations. *P* values were determined by using Student's *t* test, comparing all conditions to the control knockdown/empty vector conditions (***, *P* \leq 0.001). (E) Western blot analysis of A673 cells infected with a control shRNA (Luc) or a KRT17 shRNA and reexpressing an empty vector, KRT17 cDNA, or a constitutively active (myristoylated) form of AKT. The protein lysates from these cells were probed with KRT17, phosphorylated AKT (S473), and total AKT antibodies. Tubulin was used as a loading control. (F) Adhesion assay with the A673 cells described above for panel E. Error bars indicate standard deviations. The *P* value was determined by using Student's *t* test, comparing the KRT17 knockdown/empty vector conditions to the control knockdown/empty vector conditions (***, *P* \leq 0.001). (G) Adhesion assay with A673 cells treated with the selective AKT inhibitor or the vehicle control for 24 h. Error bars indicate standard deviations. The *P* value was determined by using Student's *t* test, comparing the inhibitor-treated conditions to the vehicle-treated conditions (***, *P* \leq 0.001).

cellular adhesion mediated by KRT17, we took two complementary approaches: (i) a genetic approach by expressing a constitutively active form of AKT (myristoylated AKT) (28) and (ii) a pharmacological approach using a selective AKT inhibitor (Akti1/2; Millipore). We found that expression of the constitutively active AKT following knockdown of endogenous KRT17 (Fig. 6E) phenocopied KRT17-mediated cellular adhesion (Fig. 6F). We also found that selective inhibition of AKT by the pharmacological inhibitor significantly decreased the basal levels of cellular adhesion in Ewing sarcoma cells, similar to levels achieved with KRT17 knockdown (Fig. 6G). These data clearly define the genetic and functional interaction between GLI1, KRT17, and active AKT signaling in regulating cellular adhesion in Ewing sarcoma cells.

KRT17-mediated oncogenic transformation is independent of the AKT pathway. AKT signaling is frequently activated in cancer (56). We therefore asked whether AKT phosphorylation was necessary for KRT17-mediated oncogenic transformation in Ewing sarcoma. Interestingly, the KRT17 S44A mutant, which failed to phosphorylate AKT (Fig. 6B), retained the ability to rescue KRT17 knockdown-mediated loss of transformation to an extent comparable to that of wild-type KRT17 (Fig. 7A), suggesting that oncogenic transformation by KRT17 is independent of the AKT pathway.

To directly test the contribution of active AKT signaling to Ewing sarcoma oncogenesis, we used the constitutively active form of AKT (myristoylated AKT) (28) and the selective AKT inhibitor (Akti1/2; Millipore). The constitutively active form of AKT failed to rescue the loss of oncogenic transformation following KRT17 knockdown, even though high levels of AKT phosphorylation were achieved (Fig. 6E and 7B). Pharmacological inhibition of AKT phosphorylation also had no effect on oncogenic transformation of Ewing sarcoma cells (Fig. 7C). Maintenance of AKT inhibition in the anchorage-independent environment was ensured by assessing the phosphorylation status of AKT in the colonies that did form (Fig. 7D). These results suggest that AKT signaling is completely dispensable for the anchorage-independent colony-forming phenotype of Ewing sarcoma cells. Taken together, our data highlight a central role for KRT17 downstream of GLI1 in coordinating two important, but independent, phenotypes of cancer cells, oncogenic transformation and cellular adhesion.

DISCUSSION

In this work, we identified KRT17 as an upregulated target of EWS/FLI and GLI1 in Ewing sarcoma. Furthermore, we unraveled novel functional roles for KRT17 in regulating oncogenic transformation and cellular adhesion in Ewing sarcoma: KRT17 induces AKT signaling to mediate cellular adhesion, while KRT17 modulates oncogenic transformation (as measured by colony formation under anchorage-independent conditions and by xenograft tumor formation) independent of AKT signaling. To our knowledge, this is the first demonstration of such a coordinating function for an intermediate-filament protein for these cancer-relevant phenotypes.

Hyperactive AKT signaling is characteristic of several cancers (56). Interestingly, oncogenic transformation mediated by KRT17 is independent of the AKT signaling pathway in Ewing sarcoma. Consequently, inhibition of the AKT signaling pathway had no impact on growth or oncogenic transformation of Ewing sarcoma




FIG 7 KRT17-mediated oncogenic transformation is independent of AKT signaling. (A) Quantification of colonies formed in methylcellulose by A673 cells infected with a control shRNA (Luc) or a KRT17 shRNA and reexpressing the empty vector, the KRT17 wild-type, or the S44A mutant KRT17 cDNA construct. Error bars indicate standard deviations of duplicate assays. The *P* value was determined by using Student's *t* test, comparing the conditions of a KRT17 knockdown rescued with an empty vector to those of the control knockdown rescued with an empty vector (***, $P \leq 0.001$). (B) Quantification of colonies formed in methylcellulose by A673 cells infected with a control shRNA (Luc) or a KRT17 shRNA and reexpressing an empty vector, KRT17 cDNA, or a constitutively active (myristoylated) form of AKT. Error bars indicate standard deviations of duplicate assays. *P* values were determined by using Student's *t* test, comparing all conditions to the control knockdown/empty vector conditions (***, $P \leq 0.001$). (C) Quantification of colonies formed in methylcellulose by A673 cells treated with a selective AKT inhibitor or a vehicle control for 24 h. Error bars indicate standard deviations of duplicate assays. (D) Western blot analysis of the A673 cells described above for panel C. Protein lysates from treated cells and from 3D colonies at the end of the anchorage-independent colony-forming assay were probed with phosphorylated AKT (S473) and total AKT antibodies. Tubulin was used as the loading control. The total amount of protein obtained from the 3D colonies was much smaller than that obtained from cells grown and treated on plastic.

cells. These observations suggest that cooperating molecules or pathways necessary for AKT to mediate oncogenic transformation in other cancers may be absent in Ewing sarcoma cells. Indeed, polymerization of KRT17 with KRT5/6 α /6 β is required to form stable cytoskeletal structures (43), and mutations in KRT17 or its partner KRT5, -6 α , or -6 β result in human genetic diseases. We inspected our global transcriptional profiling data sets and found very low, if any, expression for KRT5, -6 α , or -6 β in Ewing sarcoma cells, suggesting that KRT17 functions in a novel capacity to regulate oncogenic transformation. This also indicates that in addition to regulating AKT signaling, KRT17 might impinge on multiple critical growth factor signaling pathways in the context of

Ewing sarcoma cells, all of which together contribute to the transformed phenotype. Further studies are ongoing to identify the precise mechanism by which KRT17 regulates oncogenic transformation in Ewing sarcoma.

Importantly, we demonstrate in this report that KRT17-mediated AKT phosphorylation is necessary and sufficient for regulating cellular adhesion. There is a growing body of evidence indicating that alterations in the adhesion properties of cells play a pivotal role in the development and progression of cancer (57). Expression of EWS/FLI has profound effects on adhesion and cytoskeletal architecture of Ewing sarcoma cells (34). In support of this are transcriptional profiling data for EWS/FLI in Ewing sarcoma cells that reveal a significant downregulation of adhesion and cytoskeletal proteins, suggesting that Ewing sarcoma cells have low basal levels of cellular adhesion (10). Therefore, EWS/FLI is necessary for oncogenic transformation in Ewing sarcoma, and EWS/FLI globally represses adhesion of Ewing sarcoma cells. In fact, cellular adhesion is dramatically increased upon EWS/FLI knockdown in Ewing sarcoma cells (34). *GLI1* is a direct activated target of EWS/FLI that is necessary for oncogenic transformation. Transcription profiling data suggest that *GLI1*-regulated genes in Ewing sarcoma function to both activate and repress cellular adhesion. Therefore, as we move lower in the hierarchy of transcriptional regulation away from EWS/FLI, we start segregating genes that differentially regulate oncogenic transformation versus cellular adhesion. Our data suggest that the direct *GLI1* target gene *KRT17* functions to positively regulate oncogenic transformation in the same way as EWS/FLI and *GLI1*. However, contrary to the role of EWS/FLI in significantly repressing cellular adhesion or the role of *GLI1* in activating as well as repressing genes that regulate cellular adhesion, *KRT17* functions to positively regulate cellular adhesion in Ewing sarcoma.

Ewing sarcoma is a highly metastatic tumor, and in the absence of chemotherapy, the vast majority of patients die from metastatic disease, suggesting that most patients have micrometastases at presentation (58, 59). In support of this, circulating tumor cells can be identified in Ewing sarcoma patients (60). These observations suggest that, in contrast to epithelial cell cancers, which are thought to follow a multistep process for metastasis, a mesenchymal tumor such as Ewing sarcoma may display metastatic dissemination of tumor cells early in the disease process (34). The ability of Ewing sarcoma tumor cells to readily disseminate clearly highlights the importance of regulating adhesion levels in these tumors. Although EWS/FLI largely inhibits cellular adhesion proteins likely to promote metastatic dissemination in Ewing sarcoma, these tumor cells still need to maintain low basal levels of adhesion to be able to form tumors and to adhere to and colonize secondary sites of metastasis. Our data suggest that *KRT17* is one of the critical cytoskeletal proteins downstream of EWS/FLI and *GLI1* that is necessary to maintain basal levels of cellular adhesion in Ewing sarcoma by activating the AKT signaling pathway. Interestingly, the AKT signaling pathway was previously shown to activate focal adhesion kinase (FAK)-dependent adhesion in cancer (61), further supporting our finding that AKT signaling regulates cellular adhesion in Ewing sarcoma.

Our data in this study suggest that AKT signaling uncouples *KRT17*-mediated cellular adhesion and oncogenic transformation in Ewing sarcoma. A similar uncoupling of cellular adhesion and oncogenic transformation was previously noted for activated Src kinase signaling. Src kinase expression/activity is frequently

increased in various cancers, where it affects oncogenic transformation by activating RAS, phosphatidylinositol 3-kinase (PI3K), and STAT signaling pathways (62). Activated mutants of Src play a role in oncogenic transformation and affect morphological changes, including cellular adhesion (63). Interestingly, it has been shown that integrin $\alpha 5\beta 3$ signaling regulates Src kinase-mediated oncogenic transformation, but this interaction does not affect Src-mediated cellular adhesion (64). Our data suggest that signaling downstream of *KRT17* may occur through multiple independent pathways, one of which is AKT signaling, which is necessary for cellular adhesion but dispensable for oncogenic transformation.

Based on our findings, we hypothesize that inhibition of the AKT signaling pathway alone would be an ineffective therapy for Ewing sarcoma patients. In support of this are the findings that insulin-like growth factor 1 receptor (IGF1R) antagonists that have shown efficacy in phase I/II clinical trials for the treatment of Ewing sarcoma patients (65, 66) inhibit not only PI3K-AKT signaling but also the RAS-mitogen-activated protein kinase (MAPK) and JAK-STAT pathways. Therefore, inhibition of multiple crucial signaling pathways may be necessary to inhibit growth and transformation of Ewing sarcoma cells. Also, targeting of pathways downstream of IGF1R with MEK/MAPK inhibitors (PD98059 and U0126) and a PI3K inhibitor (LY294002) decreases Ewing sarcoma cell survival and increases sensitivity to doxorubicin (67). Interestingly, blocking of AKT activation alone did not have any effect on survival or proliferation of Ewing sarcoma cells (S. Sankar, unpublished observations). Our results demonstrate that active AKT signaling is not required for proliferation or oncogenic transformation in Ewing sarcoma.

In conclusion, we have defined a new pathway downstream of *GLI1* in Ewing sarcoma that highlights the central role of *KRT17* in coordinating both oncogenic transformation and cellular adhesion in Ewing sarcoma. Future work will be required to identify the critical factors and pathways downstream of *KRT17* that affect oncogenic transformation. These studies will be key to a better understanding of the biology of Ewing sarcoma and may lead to more effective targeted therapies for patients with this devastating disease.

ACKNOWLEDGMENTS

S.S. acknowledges support from the HHMI Med into Grad program at the University of Utah (U2M2G). This work was supported by NIH/NCI grants R01 CA140394 (to S.L.L.) and P30 CA042014 (to the Huntsman Cancer Institute).

We thank Alana Welm for discussions and critical reading of the manuscript and for generously providing us with immunodeficient mice, Michael Monument for providing the Ewing sarcoma patient tumor RNA, and Wen Luo and members of the Lessnick and Beckerle laboratories for helpful discussions and reagents.

REFERENCES

- Arndt CA, Crist WM. 1999. Common musculoskeletal tumors of childhood and adolescence. *N. Engl. J. Med.* 341:342–352.
- Delattre O, Zucman J, Plougastel B, Desmaziere C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, Aurias A, Thomas G. 1992. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. *Nature* 359:162–165.
- Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, Lessnick SL. 2006. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. *Cancer Cell* 9:405–416.
- Kinsey M, Smith R, Lessnick SL. 2006. NR0B1 is required for the onco-

- genic phenotype mediated by EWS/FLI in Ewing's sarcoma. *Mol. Cancer Res.* 4:851–859.
5. Prieur A, Tirode F, Cohen P, Delattre O. 2004. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. *Mol. Cell. Biol.* 24:7275–7283.
 6. Shukla N, Ameer N, Yilmaz I, Nafa K, Lau CY, Marchetti A, Borsu L, Barr FG, Ladanyi M. 2012. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. *Clin. Cancer Res.* 18:748–757.
 7. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M. 2005. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. *J. Clin. Oncol.* 23:548–558.
 8. May WA, Lessnick SL, Braun BS, Klemz M, Lewis BC, Lunsford LB, Hromas R, Denny CT. 1993. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. *Mol. Cell. Biol.* 13:7393–7398.
 9. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, Zucman J, Thomas G, Denny CT. 1993. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. *Proc. Natl. Acad. Sci. U. S. A.* 90:5752–5756.
 10. Owen LA, Kowalewski AA, Lessnick SL. 2008. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. *PLoS One* 3:e1965. doi:10.1371/journal.pone.0001965.
 11. Kasper M, Regl G, Frischauf AM, Aberger F. 2006. GLI transcription factors: mediators of oncogenic Hedgehog signalling. *Eur. J. Cancer* 42:437–445.
 12. Ingham PW, McMahon AP. 2001. Hedgehog signaling in animal development: paradigms and principles. *Genes Dev.* 15:3059–3087.
 13. Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, Tonn J, Sorensen N, Berthold F, Henk B, Schmandt N, Wolf HK, von Deimling A, Wainwright B, Chenevix-Trench G, Wiessler OD, Wicking C. 1997. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of *Drosophila* patched. *Cancer Res.* 57:2085–2088.
 14. Tostar U, Malm CJ, Meis-Kindblom JM, Kindblom LG, Toftgard R, Unden AB. 2006. Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. *J. Pathol.* 208:17–25.
 15. Hahn H, Wicking C, Zaphiropoulos PG, Gailani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E, Unden AB, Gillies S, Negus K, Smyth I, Pressman C, Leffell DJ, Gerrard B, Goldstein AM, Dean M, Toftgard R, Chenevix-Trench G, Wainwright B, Bale AE. 1996. Mutations of the human homolog of *Drosophila* patched in the nevoid basal cell carcinoma syndrome. *Cell* 85:841–851.
 16. Sheng T, Li C, Zhang X, Chi S, He N, Chen K, McCormick F, Gatalica Z, Xie J. 2004. Activation of the hedgehog pathway in advanced prostate cancer. *Mol. Cancer* 3:29. doi:10.1186/1476-4598-3-29.
 17. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M. 2003. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. *Nature* 425:851–856.
 18. Bian YH, Huang SH, Yang L, Ma XL, Xie JW, Zhang HW. 2007. Sonic hedgehog-Gli1 pathway in colorectal adenocarcinomas. *World J. Gastroenterol.* 13:1659–1665.
 19. Chi S, Huang S, Li C, Zhang X, He N, Bhutani MS, Jones D, Castro CY, Logrono R, Haque A, Zwischenberger J, Tyring SK, Zhang H, Xie J. 2006. Activation of the hedgehog pathway in a subset of lung cancers. *Cancer Lett.* 244:53–60.
 20. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, Beachy PA. 2003. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. *Nature* 425:846–851.
 21. Ruiz i Altaba A, Sanchez P, Dahmane N. 2002. Gli and hedgehog in cancer: tumours, embryos and stem cells. *Nat. Rev. Cancer* 2:361–372.
 22. Riobo NA, Lu K, Emerson CP, Jr. 2006. Hedgehog signal transduction: signal integration and cross talk in development and cancer. *Cell Cycle* 5:1612–1615.
 23. Sankar S, Bell R, Patel M, Davis IJ, Lessnick SL, Luo W. 17 May 2013. EWS and RE1-silencing transcription factor inhibit neuronal phenotype development and oncogenic transformation in Ewing sarcoma. *Genes Cancer* [Epub ahead of print.] doi:10.1177/1947601913489569.
 24. Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W, Endo Y, Rubin JS, Toretsky J, Uren A. 2009. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. *J. Biol. Chem.* 284:9074–9082.
 25. Zwerner JP, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ, May WA. 2008. The EWS/FLI1 oncogenic transcription factor deregulates GLI1. *Oncogene* 27:3282–3291.
 26. Joo J, Christensen L, Warner K, States L, Kang HG, Vo K, Lawlor ER, May WA. 2009. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. *PLoS One* 4:e7608. doi:10.1371/journal.pone.0007608.
 27. Braunreiter CL, Hancock JD, Coffin CM, Boucher KM, Lessnick SL. 2006. Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma. *Cell Cycle* 5:2753–2759.
 28. Zhang J, Lodish HF. 2004. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors. *Blood* 104:1679–1687.
 29. Lessnick SL, Dacwag CS, Golub TR. 2002. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. *Cancer Cell* 1:393–401.
 30. Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL. 26 November 2012. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. *Oncogene* [Epub ahead of print.] doi:10.1038/nc.2012.525.
 31. Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, Boucher KM, Watkins WS, Jorde LB, Graves BJ, Lessnick SL. 2008. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. *Proc. Natl. Acad. Sci. U. S. A.* 105:10149–10154.
 32. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. 2007. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. *Genes Dev.* 21:1882–1894.
 33. Oler AJ, Alla RK, Roberts DN, Wong A, Hollenhorst PC, Chandler KJ, Cassidy PA, Nelson CA, Hagedorn CH, Graves BJ, Cairns BR. 2010. Human RNA polymerase III transcriptomes and relationships to Pol II promoter chromatin and enhancer-binding factors. *Nat. Struct. Mol. Biol.* 17:620–628.
 34. Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle MC. 2012. The EWS/FLI oncogene drives changes in cellular morphology, adhesion, and migration in Ewing sarcoma. *Genes Cancer* 3:102–116.
 35. Hui CC, Angers S. 2011. Gli proteins in development and disease. *Annu. Rev. Cell Dev. Biol.* 27:513–537.
 36. Yoon JW, Kita Y, Frank DJ, Majewski RR, Konicek BA, Nobrega MA, Jacob H, Walterhouse D, Iannaccone P. 2002. Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. *J. Biol. Chem.* 277:5548–5555.
 37. Cavazzana AO, Miser JS, Jefferson J, Triche TJ. 1987. Experimental evidence for a neural origin of Ewing's sarcoma of bone. *Am. J. Pathol.* 127:507–518.
 38. Lipinski M, Hirsch MR, Deagostini-Bazin H, Yamada O, Tursz T, Goridis C. 1987. Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines. *Int. J. Cancer* 40:81–86.
 39. Hallikas O, Palin K, Sinjushina N, Rautiainen R, Partanen J, Ukkonen E, Taipale J. 2006. Genome-wide prediction of mammalian enhancers based on analysis of transcription-factor binding affinity. *Cell* 124:47–59.
 40. Winklmayr M, Schmid C, Laner-Plamberger S, Kaser A, Aberger F, Eichberger T, Frischauf AM. 2010. Non-consensus GLI binding sites in Hedgehog target gene regulation. *BMC Mol. Biol.* 11:2. doi:10.1186/1471-2199-11-2.
 41. Grant CE, Bailey TL, Noble WS. 2011. FIMO: scanning for occurrences of a given motif. *Bioinformatics* 27:1017–1018.
 42. Ohali A, Avigad S, Zaizov R, Ophir R, Horn-Saban S, Cohen IJ, Meller I, Kollender Y, Issakov J, Yaniv I. 2004. Prediction of high risk Ewing's sarcoma by gene expression profiling. *Oncogene* 23:8997–9006.
 43. Coulombe PA, Tong X, Mazzalupo S, Wang Z, Wong P. 2004. Great promises yet to be fulfilled: defining keratin intermediate filament function in vivo. *Eur. J. Cell Biol.* 83:735–746.
 44. Depianto D, Kerns ML, Dlugosz AA, Coulombe PA. 2010. Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin. *Nat. Genet.* 42:910–914.
 45. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J, Hajduduch M, Murray

- P, Kolar Z. 2007. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. *BMC Cancer* 7:55. doi:10.1186/1471-2407-7-55.
46. Smedts F, Ramaekers F, Troyanovsky S, Pruszczynski M, Link M, Lane B, Leigh I, Schijf C, Vooijs P. 1992. Keratin expression in cervical cancer. *Am. J. Pathol.* 141:497–511.
 47. Bournet B, Pointreau A, Souque A, Oumouhou N, Muscari F, Lepage B, Senesse P, Barthet M, Lesavre N, Hammel P, Levy P, Ruzniewski P, Cordelier P, Buscail L. 2012. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. *Pancreatology* 12:27–34.
 48. Zhang J, Wang K, Liu SS, Dai L, Zhang JY. 2011. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. *J. Proteome Res.* 10:2863–2872.
 49. Shi I, Hashemi Sadraei N, Duan ZH, Shi T. 2011. Aberrant signaling pathways in squamous cell lung carcinoma. *Cancer Inform.* 10:273–285.
 50. Ossandon FJ, Villarroel C, Aguayo F, Santibanez E, Oue N, Yasui W, Corvalan AH. 2008. In silico analysis of gastric carcinoma. Serial analysis of gene expression libraries reveals different profiles associated with ethnicity. *Mol. Cancer* 7:22. doi:10.1186/1476-4598-7-22.
 51. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P. 2002. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. *Am. J. Pathol.* 161:1991–1996.
 52. Ide M, Kato T, Ogata K, Mochiki E, Kuwano H, Oyama T. 2012. Keratin 17 expression correlates with tumor progression and poor prognosis in gastric adenocarcinoma. *Ann. Surg. Oncol.* 19:3506–3514.
 53. Sarbia M, Fritze F, Geddert H, von Weyhern C, Rosenberg R, Gellert K. 2007. Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful? *Am. J. Clin. Pathol.* 128:255–259.
 54. Kim S, Wong P, Coulombe PA. 2006. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. *Nature* 441:362–365.
 55. Pan X, Kane LA, Van Eyk JE, Coulombe PA. 2011. Type I keratin 17 protein is phosphorylated on serine 44 by p90 ribosomal protein S6 kinase 1 (RSK1) in a growth- and stress-dependent fashion. *J. Biol. Chem.* 286:42403–42413.
 56. Altomare DA, Testa JR. 2005. Perturbations of the AKT signaling pathway in human cancer. *Oncogene* 24:7455–7464.
 57. Okegawa T, Pong RC, Li Y, Hsieh JT. 2004. The role of cell adhesion molecule in cancer progression and its application in cancer therapy. *Acta Biochim. Pol.* 51:445–457.
 58. Dahlin DC, Coventry MB, Scanlon PW. 1961. Ewing's sarcoma. A critical analysis of 165 cases. *J. Bone Joint Surg. Am.* 43-A:185–192.
 59. Wang CC, Schulz MD. 1953. Ewing's sarcoma; a study of fifty cases treated at the Massachusetts General Hospital, 1930-1952 inclusive. *N. Engl. J. Med.* 248:571–576.
 60. Dubois SG, Epling CL, Teague J, Matthay KK, Sinclair E. 2010. Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. *Pediatr. Blood Cancer* 54:13–18.
 61. Wang S, Basson MD. 2011. Protein kinase B/AKT and focal adhesion kinase: two close signaling partners in cancer. *Anticancer Agents Med. Chem.* 11:993–1002.
 62. Irby RB, Yeatman TJ. 2000. Role of Src expression and activation in human cancer. *Oncogene* 19:5636–5642.
 63. Yeatman TJ. 2004. A renaissance for SRC. *Nat. Rev. Cancer* 4:470–480.
 64. Huvneers S, Arslan S, van de Water B, Sonnenberg A, Danen EH. 2008. Integrins uncouple Src-induced morphological and oncogenic transformation. *J. Biol. Chem.* 283:13243–13251.
 65. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Pacagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P. 2010. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. *Lancet Oncol.* 11:129–135.
 66. Kelleher FC, Thomas DM. 2012. Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours. *Clin. Sarcoma Res.* 2:6. doi:10.1186/2045-3329-2-6.
 67. Benini S, Manara MC, Cerisano V, Perdichizzi S, Strammiello R, Serra M, Picci P, Scotlandi K. 2004. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. *Int. J. Cancer* 108:358–366.